Drugs / rivogenlecleucel

Trials 12 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT03807063 Jan → Dec 2020 B-cell chronic lymphocytic leukemia, CD4+/CD56+ hematodermic neoplasm, acute biphenotypic leukemia, bilineal acute myeloid leukemia +4 Fred Hutchinson Cancer Center Withdrawn No outcome recorded
Phase 1 NCT03459170 Feb 2018 → Sep 2022 overdue hematopoietic and lymphoid cell neoplasm Bellicum Pharmaceuticals Active not recruiting No outcome recorded
Phase 1 NCT02487459 Jul 2016 → Jun 2017 hematopoietic and lymphoid cell neoplasm Bellicum Pharmaceuticals Withdrawn No outcome recorded
Phase 1 NCT02477878 Jul 2016 → Jan 2020 overdue leukemia, myelodysplastic syndrome, plasma cell myeloma Bellicum Pharmaceuticals Active not recruiting No outcome recorded
Phase 1 NCT02786485 May 2016 → Dec 2018 leukemia, myelodysplastic syndrome, plasma cell myeloma Bellicum Pharmaceuticals Withdrawn No outcome recorded
Phase 1 NCT02231710 Feb → Sep 2015 bone marrow failure syndrome, hemoglobinopathy, hemophagocytic syndrome, immunodeficiency disease +1 Bellicum Pharmaceuticals Terminated No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT03733249 Jan 2017 → Jun 2020 Diamond-Blackfan anemia, Fanconi anemia, acute lymphoblastic leukemia, childhood acute myeloid leukemia +5 Bellicum Pharmaceuticals Terminated No outcome recorded
Phase 1/2 NCT03301168 Apr 2014 → May 2021 overdue acute lymphoblastic leukemia, aplastic anemia, childhood acute myeloid leukemia, hemoglobinopathy +3 Bellicum Pharmaceuticals Active not recruiting No outcome recorded
Phase 1/2 NCT02065869 Apr 2014 → Jun 2020 Diamond-Blackfan anemia, Fanconi anemia, acute lymphoblastic leukemia, childhood acute myeloid leukemia +5 Bellicum Pharmaceuticals Terminated No outcome recorded
Phase 1/2 NCT01744223 Mar 2013 → Oct 2019 overdue acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome Bellicum Pharmaceuticals Active not recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT03699475 Dec 2018 → Jul 2019 acute myeloid leukemia, myelodysplastic syndrome Bellicum Pharmaceuticals Terminated No outcome recorded
Phase not stated1 trial
NCT03639844 Hurler syndrome, metachromatic leukodystrophy Bellicum Pharmaceuticals No longer available No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as Rivogenlecleucel “Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients...” NCT02065869
5

NCT03733249

NCT03639844

NCT03807063

NCT02786485

NCT03699475

Known as BPX 501 “a BPX 501 infusion (T cells genetically modified with the inducible Caspase 9 suicide gene)” NCT02231710
5

NCT02477878

NCT02231710

NCT02065869

NCT01744223

NCT02487459

Known as BPX-501 T cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT03301168
1

NCT03459170

Modality Cell therapy “2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501)” NCT01744223
Route Other “BPX-501 infused after partially mismatched, related (haploidentical), T cell-depleted HSCT” NCT01744223